What is Quince Therapeutics, Inc.'s market cap?

Quince Therapeutics, Inc. (QNCX) has a market capitalization of $17.1M and trades on NASDAQ.

Who are Quince Therapeutics, Inc.'s competitors?

Quince Therapeutics, Inc.'s key competitors include Sarepta Therapeutics, PTC Therapeutics, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Quince Therapeutics, Inc. partner with?

Quince Therapeutics, Inc.'s notable partners include LifeSci Capital, Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC, and others.

What subsidiaries does Quince Therapeutics, Inc. have?

Quince Therapeutics, Inc.'s subsidiaries include EryDel S.p.A..

Where is Quince Therapeutics, Inc. headquartered?

Quince Therapeutics, Inc. is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 2019.

Quince Therapeutics, Inc.

QNCX

Quince Therapeutics is a biotechnology company that historically focused on developing innovative drug-delivery treatments for rare diseases using its proprietary AIDE technology platform.

Market cap

$17.1M-81.6%

Table of contents

Earnings

Q1 2026 report

May 11, 2026

EPS-$0.59Beat by $0.71

Read the full report

Next report

Aug 11, 2026 (in a month)

EPS estimate-$25.40

Competitors

By market cap

PTC Therapeutics$7.4B+95.3%

Sarepta Therapeutics, Inc.$2.2B+27.3%

ANI Pharmaceuticals$1.9B+35.5%

Eton Pharmaceuticals, Inc.$1.0B+165%

Zevra Therapeutics, Inc.$824.1M+33.7%

Fulcrum Therapeutics, Inc.$239.2M-36.9%

Polaryx Therapeutics, Inc. $121.1M—

Quince Therapeutics, Inc.$17.1M-79.9%

By revenue growth

Zevra Therapeutics, Inc.+201%

Eton Pharmaceuticals, Inc.+79.9%

ANI Pharmaceuticals+37.0%

Sarepta Therapeutics, Inc.+9.9%

PTC Therapeutics-53.3%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

PTC Therapeutics42.25%+119pp

ANI Pharmaceuticals9.98%+13.1pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Profile

Quince Therapeutics is a biotechnology company that historically focused on developing innovative drug-delivery treatments for rare diseases using its proprietary AIDE technology platform. The platform utilizes an automated process to encapsulate drugs into a patient's own red blood cells to improve safety, tolerability, and biodistribution. Following the clinical failure of its lead asset in a Phase 3 trial, the company has ceased all research and development activities and is currently focused on preserving cash while evaluating strategic alternatives, including a potential reverse merger.

Competitive position

The company is currently in a distressed state, having discontinued its primary development programs and seeking strategic alternatives to maximize remaining shareholder value.

GeographiesUnited States, Italy, European Union

Customer segmentsPatients, Healthcare Providers

Business modelResearch and Development, IP Licensing

SuppliersThird-party component manufacturers, Specialized medical device suppliers, Clinical trial service providers

CustomersSpecialized medical centers, Rare disease patient populations

CountryUnited States of America

Listed2019

Employees32.0

CEODirk Thye

SectorHealthcare

IndustryBiotechnology

Websitequincetx.com

FilingsSEC EDGAR

Questions, answered.

What is Quince Therapeutics, Inc.'s market cap?: Quince Therapeutics, Inc. (QNCX) has a market capitalization of $17.1M and trades on NASDAQ.
Who are Quince Therapeutics, Inc.'s competitors?: Quince Therapeutics, Inc.'s key competitors include Sarepta Therapeutics, PTC Therapeutics, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Quince Therapeutics, Inc. partner with?: Quince Therapeutics, Inc.'s notable partners include LifeSci Capital, Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC, and others.
What subsidiaries does Quince Therapeutics, Inc. have?: Quince Therapeutics, Inc.'s subsidiaries include EryDel S.p.A..
Where is Quince Therapeutics, Inc. headquartered?: Quince Therapeutics, Inc. is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 2019.